Literature DB >> 3069984

The clinical use of disulfiram (Antabuse): a review.

P Banys1.   

Abstract

Disulfiram is a potent alcohol-sensitizing drug, the effectiveness of which remains unproven in the treatment of alcoholism after 40 years of use. Its clinical utility is more closely associated with nonspecific, nonpharmacological factors (such as social class, patient compliance, patient personality characteristics, and treatment structure) than with its aversive biochemistry. Disulfiram is not effective as a sole alternative to a structured treatment program. Disulfiram retains a place in standard alcoholism treatment programs because clinicians have found this agent useful for selected alcoholic patients. Clinical studies and clinical lore describe these patients as older, relapse-prone, socially stable, cognitively intact, not depressed, compulsive, capable of following rules, and tolerant of dependence. Another distinctly responsive (but evasive) group is court-probated patients. These characteristics also describe patients who are well-known to have good outcomes without disulfiram, thus they do not help clinicians to select suitable patients for this medication. Consequently, this article proposes the following selection criteria: (1) patients who can tolerate a treatment relationship; (2) patients who are relapse-prone (but in treatment); (3) patients who have failed with less structured approaches; (4) patients in early abstinence who are in crisis or under severe stress; (5) patients in established recovery for whom individual or group psychotherapy is a relapse risk; and (6) patients who specifically request it. With or without disulfiram, a treatment program needs to be highly structured and predictable in order to be useful to newly recovering patients. Recovery is a process with discernible phases of development, and the provision of structure is the core of early treatment, where behavior change is more important than insight. A well-structured program will have phases through which a patient may progress. Generally speaking, disulfiram is most useful early to establish sobriety and to allow time for other support structures, such as AA, therapist-patient relationships, and new personal relationships, to take hold. Disulfiram is best given to patients with prior treatment failures, early in treatment, briefly during crises in established sobriety, or to support unusual stresses, such as psychotherapy. Prescriptions should be short-term and not allow automatic refills. It should be necessary to attend a treatment program in order to obtain them. Supervision and monitoring dramatically increase compliance.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069984     DOI: 10.1080/02791072.1988.10472495

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  11 in total

Review 1.  Situational Strategies for Self-Control.

Authors:  Angela L Duckworth; Tamar Szabó Gendler; James J Gross
Journal:  Perspect Psychol Sci       Date:  2016-01

2.  Behavior Change.

Authors:  Angela L Duckworth; James J Gross
Journal:  Organ Behav Hum Decis Process       Date:  2020-12-10

3.  A Stitch in Time: Strategic Self-Control in High School and College Students.

Authors:  Angela L Duckworth; Rachel E White; Alyssa J Matteucci; Annie Shearer; James J Gross
Journal:  J Educ Psychol       Date:  2016-04

4.  OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. First evaluation of a new approach.

Authors:  H Ehrenreich; A Mangholz; M Schmitt; P Lieder; W Völkel; E Rüther; W Poser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 5.  Recommended drug treatment strategies for the alcoholic patient.

Authors:  A Schaffer; C A Naranjo
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

6.  Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase.

Authors:  W M Keung; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

Review 7.  Medications for substance use disorders.

Authors:  Antoine B Douaihy; Thomas M Kelly; Carl Sullivan
Journal:  Soc Work Public Health       Date:  2013

8.  Daidzin suppresses ethanol consumption by Syrian golden hamsters without blocking acetaldehyde metabolism.

Authors:  W M Keung; O Lazo; L Kunze; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

9.  Abstinence-dependent transfer of lithium chloride-induced sucrose aversion to a sucrose-paired cue in rats.

Authors:  John H Harkness; Sierra Webb; Jeffrey W Grimm
Journal:  Psychopharmacology (Berl)       Date:  2009-12-29       Impact factor: 4.530

10.  The pharmacotherapy of alcohol dependence: a state of the art review.

Authors:  Avinash De Sousa
Journal:  Mens Sana Monogr       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.